196 related articles for article (PubMed ID: 37558687)
21. The role of epithelial mesenchymal transition markers in thyroid carcinoma progression.
Montemayor-Garcia C; Hardin H; Guo Z; Larrain C; Buehler D; Asioli S; Chen H; Lloyd RV
Endocr Pathol; 2013 Dec; 24(4):206-12. PubMed ID: 24126800
[TBL] [Abstract][Full Text] [Related]
22. Diagnostic utility of CK19 and CD56 in the differentiation of thyroid papillary carcinoma from its mimics.
Abouhashem NS; Talaat SM
Pathol Res Pract; 2017 May; 213(5):509-517. PubMed ID: 28214214
[TBL] [Abstract][Full Text] [Related]
23. Clinical significance of E-cadherin expression in thyroid neoplasms.
Naito A; Iwase H; Kuzushima T; Nakamura T; Kobayashi S
J Surg Oncol; 2001 Mar; 76(3):176-80. PubMed ID: 11276021
[TBL] [Abstract][Full Text] [Related]
24. Claudin-7 immunohistochemistry in renal tumors: a candidate marker for chromophobe renal cell carcinoma identified by gene expression profiling.
Hornsby CD; Cohen C; Amin MB; Picken MM; Lawson D; Yin-Goen Q; Young AN
Arch Pathol Lab Med; 2007 Oct; 131(10):1541-6. PubMed ID: 17922590
[TBL] [Abstract][Full Text] [Related]
25. Proximal CD13 Versus Distal GATA-3 Expression in Renal Neoplasia According to WHO 2016 Classification.
Brunelli M; Erdini F; Cima L; Eccher A; Fioravanzo A; Gobbo S; Segala D; Ghimenton C; Mazzoleni G; Munari E; Carella R; Martignoni G
Appl Immunohistochem Mol Morphol; 2018; 26(5):316-323. PubMed ID: 27556823
[TBL] [Abstract][Full Text] [Related]
26. Expression of aquaporins and PAX-2 compared to CD10 and cytokeratin 7 in renal neoplasms: a tissue microarray study.
Mazal PR; Stichenwirth M; Koller A; Blach S; Haitel A; Susani M
Mod Pathol; 2005 Apr; 18(4):535-40. PubMed ID: 15502805
[TBL] [Abstract][Full Text] [Related]
27. [Expression and clinical significance of kidney injury molecule-1 in renal epithelial neoplasms].
Dong YC; Wu B; Wang JD; Rao Q; Ma HH; Zhang RS; Zhou HB; Lu ZF; Zhou XJ
Zhonghua Bing Li Xue Za Zhi; 2010 Jan; 39(1):35-9. PubMed ID: 20388397
[TBL] [Abstract][Full Text] [Related]
28. Expression of the Na+/K+-transporting ATPase gamma subunit FXYD2 in renal tumors.
Gaut JP; Crimmins DL; Lockwood CM; McQuillan JJ; Ladenson JH
Mod Pathol; 2013 May; 26(5):716-24. PubMed ID: 23196795
[TBL] [Abstract][Full Text] [Related]
29. Fluorescent and chromogenic in situ hybridization of CEN17q as a potent useful diagnostic marker for Birt-Hogg-Dubé syndrome-associated chromophobe renal cell carcinomas.
Kato I; Iribe Y; Nagashima Y; Kuroda N; Tanaka R; Nakatani Y; Hasumi H; Yao M; Furuya M
Hum Pathol; 2016 Jun; 52():74-82. PubMed ID: 26980015
[TBL] [Abstract][Full Text] [Related]
30. Napsin A and thyroid transcription factor-1 expression in carcinomas of the lung, breast, pancreas, colon, kidney, thyroid, and malignant mesothelioma.
Bishop JA; Sharma R; Illei PB
Hum Pathol; 2010 Jan; 41(1):20-5. PubMed ID: 19740516
[TBL] [Abstract][Full Text] [Related]
31. MUC1 mucin gene, transcripts, and protein in adenomas and papillary carcinomas of the thyroid.
Bièche I; Ruffet E; Zweibaum A; Vildé F; Lidereau R; Franc B
Thyroid; 1997 Oct; 7(5):725-31. PubMed ID: 9349575
[TBL] [Abstract][Full Text] [Related]
32. PAX 8 expression in non-neoplastic tissues, primary tumors, and metastatic tumors: a comprehensive immunohistochemical study.
Ozcan A; Shen SS; Hamilton C; Anjana K; Coffey D; Krishnan B; Truong LD
Mod Pathol; 2011 Jun; 24(6):751-64. PubMed ID: 21317881
[TBL] [Abstract][Full Text] [Related]
33. NDRG1 protein overexpression in malignant thyroid neoplasms.
Gerhard R; Nonogaki S; Fregnani JH; Soares FA; Nagai MA
Clinics (Sao Paulo); 2010 Jun; 65(8):757-62. PubMed ID: 20835551
[TBL] [Abstract][Full Text] [Related]
34. Evaluation of galectin-8 expression in thyroid tumors.
Savin S; Cvejić D; Janković M; Isić T; Paunović I; Tatić S
Med Oncol; 2009; 26(3):314-8. PubMed ID: 19009371
[TBL] [Abstract][Full Text] [Related]
35. Expanding the morphologic spectrum of chromophobe renal cell carcinoma: A study of 8 cases with papillary architecture.
Michalova K; Tretiakova M; Pivovarcikova K; Alaghehbandan R; Perez Montiel D; Ulamec M; Osunkoya A; Trpkov K; Yuan G; Grossmann P; Sperga M; Ferak I; Rogala J; Mareckova J; Pitra T; Kolar J; Michal M; Hes O
Ann Diagn Pathol; 2020 Feb; 44():151448. PubMed ID: 31918172
[TBL] [Abstract][Full Text] [Related]
36. The role of cytokeratin 19 in the differential diagnosis of true papillary carcinoma of thyroid and papillary carcinoma-like changes in Graves' disease.
Erkiliç S; Koçer NE
Endocr Pathol; 2005; 16(1):63-6. PubMed ID: 16000848
[TBL] [Abstract][Full Text] [Related]
37. The diagnostic and prognostic utility of claudin expression in renal cell neoplasms.
Lechpammer M; Resnick MB; Sabo E; Yakirevich E; Greaves WO; Sciandra KT; Tavares R; Noble LC; DeLellis RA; Wang LJ
Mod Pathol; 2008 Nov; 21(11):1320-9. PubMed ID: 18587324
[TBL] [Abstract][Full Text] [Related]
38. [Cytokeratin expression of benign and malignant epithelial thyroid gland tumors. An immunohistologic study of 154 neoplasms using 8 different monoclonal cytokeratin antibodies].
Schröder S; Wodzynski A; Padberg B
Pathologe; 1996 Nov; 17(6):425-32. PubMed ID: 9082363
[TBL] [Abstract][Full Text] [Related]
39. CCNA1 gene as a potential diagnostic marker in papillary thyroid cancer.
da Silva RM; Santos JN; Uno M; Chammas R; Kulcsar MAV; Sant'Anna LB; Canevari RA
Acta Histochem; 2020 Dec; 122(8):151635. PubMed ID: 33007517
[TBL] [Abstract][Full Text] [Related]
40. Kidney-specific cadherin correlates with the ontogenetic origin of renal cell carcinoma subtypes: an indicator of a malignant potential?
Horstmann M; Geiger LM; Vogel U; Schmid H; Hennenlotter J; Kuehs U; Merseburger AS; Kruck S; Stenzl A; Bedke J
World J Urol; 2012 Aug; 30(4):525-31. PubMed ID: 21928123
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
